Youla Tsantrizos, Ph.D. - Publications

Affiliations: 
1997- Chemistry McGill University, Montreal, QC, Canada 
Area:
Crystallography
Website:
http://tsantrizos-group.mcgill.ca/tsantrizos.html

69 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Feng Y, Park J, Li SG, Boutin R, Viereck P, Schilling M, Berghuis AM, Tsantrizos YS. Chirality-Driven Mode of Binding of α-Aminophosphonic Acid-Based Allosteric Inhibitors of the Human Farnesyl Pyrophosphate Synthase (hFPPS). Journal of Medicinal Chemistry. PMID 31577901 DOI: 10.1021/acs.jmedchem.9b01104  0.6
2019 Yuan M, Mbaezue II, Zhou Z, Topic F, Tsantrizos YS. P-Chiral, N-phosphoryl sulfonamide Brønsted acids with an intramolecular hydrogen bond interaction that modulates organocatalysis. Organic & Biomolecular Chemistry. PMID 31535120 DOI: 10.1039/c9ob01774g  0.32
2019 Li SG, Yuan M, Topić F, Han ZS, Senanayake CH, Tsantrizos YS. Asymmetric Library Synthesis of P-Chiral t-Butyl-Substituted Secondary and Tertiary Phosphine Oxides. The Journal of Organic Chemistry. PMID 31099249 DOI: 10.1021/acs.joc.9b00945  0.32
2019 Waller DD, Park J, Tsantrizos YS. Inhibition of farnesyl pyrophosphate (FPP) and/or geranylgeranyl pyrophosphate (GGPP) biosynthesis and its implication in the treatment of cancers. Critical Reviews in Biochemistry and Molecular Biology. 1-20. PMID 30773935 DOI: 10.1080/10409238.2019.1568964  0.6
2018 Lacbay CM, Waller DD, Park J, Gomez Palou M, Vincent F, Huang XF, Ta V, Berghuis AM, Sebag M, Tsantrizos YS. Unraveling the Prenylation-Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors. Journal of Medicinal Chemistry. PMID 30016091 DOI: 10.1021/acs.jmedchem.8b00886  0.6
2018 Lacbay CM, Menni M, Bernatchez JA, Götte M, Tsantrizos YS. Pharmacophore requirements for HIV-1 reverse transcriptase inhibitors that selectively "Freeze" the pre-translocated complex during the polymerization catalytic cycle. Bioorganic & Medicinal Chemistry. PMID 29478802 DOI: 10.1016/j.bmc.2018.02.017  0.4
2018 Pelleieux S, Picard C, Lamarre-Théroux L, Dea D, Leduc V, Tsantrizos YS, Poirier J. Isoprenoids and tau pathology in sporadic Alzheimer's disease. Neurobiology of Aging. 65: 132-139. PMID 29476987 DOI: 10.1016/j.neurobiolaging.2018.01.012  0.32
2017 Park J, Rodionov D, De Schutter JW, Lin YS, Tsantrizos YS, Berghuis AM. Crystallographic and thermodynamic characterization of phenylaminopyridine bisphosphonates binding to human farnesyl pyrophosphate synthase. Plos One. 12: e0186447. PMID 29036218 DOI: 10.1371/journal.pone.0186447  0.6
2017 Park J, Leung CY, Matralis AN, Lacbay CM, Tsakos M, Fernandez De Troconiz G, Berghuis AM, Tsantrizos YS. Pharmacophore Mapping of Thienopyrimidine-Based Monophosphonate (ThP-MP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase. Journal of Medicinal Chemistry. PMID 28208018 DOI: 10.1021/acs.jmedchem.6b01888  0.64
2017 Li SG, Han ZS, Viereck P, Lee H, Kurouski D, Senanayake CH, Tsantrizos YS. Metal-Free Cycloetherification by in Situ Generated P-Stereogenic α-Diazanium Intermediates: A Convergent Synthesis of Enantiomerically Pure Dihydrobenzooxaphospholes. Organic Letters. PMID 28155279 DOI: 10.1021/acs.orglett.7b00051  0.32
2017 Park J, Zielinski M, Magder A, Tsantrizos YS, Berghuis AM. Human farnesyl pyrophosphate synthase is allosterically inhibited by its own product. Nature Communications. 8: 14132. PMID 28098152 DOI: 10.1038/ncomms14132  0.6
2016 Fader LD, Bailey M, Beaulieu E, Bilodeau F, Bonneau P, Bousquet Y, Carson RJ, Chabot C, Coulombe R, Duan J, Fenwick C, Garneau M, Halmos T, Jakalian A, James C, ... ... Tsantrizos Y, et al. Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs. Acs Medicinal Chemistry Letters. 7: 797-801. PMID 27563405 DOI: 10.1021/acsmedchemlett.6b00194  1
2016 Jansen G, Golizeh M, Martel-Lorion C, Dejgaard K, Shiao TC, Mancuso J, Tsantrizos YS, Roy R, Sebag M, Sleno L, Thomas DY, Waller DD. A covalent cysteine-targeting kinase inhibitor of Ire1 permits allosteric control of endoribonuclease activity. Chembiochem : a European Journal of Chemical Biology. PMID 26792008 DOI: 10.1002/cbic.201500485  1
2015 Moiseeva O, Lessard F, Acevedo-Aquino M, Vernier M, Tsantrizos YS, Ferbeyre G. Mutant lamin A links prophase to a p53 independent senescence program. Cell Cycle (Georgetown, Tex.). 14: 2408-21. PMID 26029982 DOI: 10.1080/15384101.2015.1053671  1
2015 Fandrick KR, Li W, Zhang Y, Tang W, Gao J, Rodriguez S, Patel ND, Reeves DC, Wu JP, Sanyal S, Gonnella N, Qu B, Haddad N, Lorenz JC, Sidhu K, ... ... Tsantrizos Y, et al. Concise and Practical Asymmetric Synthesis of a Challenging Atropisomeric HIV Integrase Inhibitor. Angewandte Chemie (International Ed. in English). 54: 7144-8. PMID 25939331 DOI: 10.1002/anie.201501575  1
2015 Gritzalis D, Park J, Chiu W, Cho H, Lin YS, De Schutter JW, Lacbay CM, Zielinski M, Berghuis AM, Tsantrizos YS. Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase. Bioorganic & Medicinal Chemistry Letters. 25: 1117-23. PMID 25630225 DOI: 10.1016/j.bmcl.2014.12.089  1
2014 Lacbay CM, Mancuso J, Lin YS, Bennett N, Götte M, Tsantrizos YS. Modular assembly of purine-like bisphosphonates as inhibitors of HIV-1 reverse transcriptase. Journal of Medicinal Chemistry. 57: 7435-49. PMID 25144111 DOI: 10.1021/jm501010f  1
2014 Zhang Y, Lu BZ, Li G, Rodriguez S, Tan J, Wei HX, Liu J, Roschangar F, Ding F, Zhao W, Qu B, Reeves D, Grinberg N, Lee H, Heckmann G, ... ... Tsantrizos Y, et al. A highly concise and convergent synthesis of HCV polymerase inhibitor Deleobuvir (BI 207127): application of a one-pot borylation-Suzuki coupling reaction. Organic Letters. 16: 4558-61. PMID 25105303 DOI: 10.1021/ol5021114  1
2014 Park J, Matralis AN, Berghuis AM, Tsantrizos YS. Human isoprenoid synthase enzymes as therapeutic targets. Frontiers in Chemistry. 2: 50. PMID 25101260 DOI: 10.3389/fchem.2014.00050  0.6
2014 Fader LD, Carson R, Morin S, Bilodeau F, Chabot C, Halmos T, Bailey MD, Kawai SH, Coulombe R, Laplante S, Mekhssian K, Jakalian A, Garneau M, Duan J, Mason SW, ... ... Tsantrizos Y, et al. Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV. Acs Medicinal Chemistry Letters. 5: 711-6. PMID 24944749 DOI: 10.1021/ml500110j  1
2014 De Schutter JW, Park J, Leung CY, Gormley P, Lin YS, Hu Z, Berghuis AM, Poirier J, Tsantrizos YS. Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases. Journal of Medicinal Chemistry. 57: 5764-76. PMID 24911527 DOI: 10.1021/jm500629e  1
2014 Fader LD, Malenfant E, Parisien M, Carson R, Bilodeau F, Landry S, Pesant M, Brochu C, Morin S, Chabot C, Halmos T, Bousquet Y, Bailey MD, Kawai SH, Coulombe R, ... ... Tsantrizos Y, et al. Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1. Acs Medicinal Chemistry Letters. 5: 422-7. PMID 24900852 DOI: 10.1021/ml500002n  1
2014 Fenwick C, Amad M, Bailey MD, Bethell R, Bös M, Bonneau P, Cordingley M, Coulombe R, Duan J, Edwards P, Fader LD, Faucher AM, Garneau M, Jakalian A, Kawai S, ... ... Tsantrizos Y, et al. Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor. Antimicrobial Agents and Chemotherapy. 58: 3233-44. PMID 24663024 DOI: 10.1128/AAC.02719-13  1
2014 Park J, Lin YS, Tsantrizos YS, Berghuis AM. Structure of human farnesyl pyrophosphate synthase in complex with an aminopyridine bisphosphonate and two molecules of inorganic phosphate. Acta Crystallographica. Section F, Structural Biology Communications. 70: 299-304. PMID 24598914 DOI: 10.1107/S2053230X14002106  1
2014 LaPlante SR, Bös M, Brochu C, Chabot C, Coulombe R, Gillard JR, Jakalian A, Poirier M, Rancourt J, Stammers T, Thavonekham B, Beaulieu PL, Kukolj G, Tsantrizos YS. Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127). Journal of Medicinal Chemistry. 57: 1845-54. PMID 24159919 DOI: 10.1021/jm4011862  1
2013 Leung CY, Park J, De Schutter JW, Sebag M, Berghuis AM, Tsantrizos YS. Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition. Journal of Medicinal Chemistry. 56: 7939-50. PMID 23998921 DOI: 10.1021/jm400946f  1
2013 Stammers TA, Coulombe R, Rancourt J, Thavonekham B, Fazal G, Goulet S, Jakalian A, Wernic D, Tsantrizos Y, Poupart MA, Bös M, McKercher G, Thauvette L, Kukolj G, Beaulieu PL. Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors. Bioorganic & Medicinal Chemistry Letters. 23: 2585-9. PMID 23545108 DOI: 10.1016/j.bmcl.2013.02.110  1
2013 Leung CY, Langille AM, Mancuso J, Tsantrizos YS. Discovery of thienopyrimidine-based inhibitors of the human farnesyl pyrophosphate synthase--parallel synthesis of analogs via a trimethylsilyl ylidene intermediate. Bioorganic & Medicinal Chemistry. 21: 2229-40. PMID 23477945 DOI: 10.1016/j.bmc.2013.02.006  1
2012 Park J, Lin YS, De Schutter JW, Tsantrizos YS, Berghuis AM. Ternary complex structures of human farnesyl pyrophosphate synthase bound with a novel inhibitor and secondary ligands provide insights into the molecular details of the enzyme's active site closure. Bmc Structural Biology. 12: 32. PMID 23234314 DOI: 10.1186/1472-6807-12-32  1
2012 De Schutter JW, Shaw J, Lin YS, Tsantrizos YS. Design of potent bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase via targeted interactions with the active site 'capping' phenyls. Bioorganic & Medicinal Chemistry. 20: 5583-91. PMID 22884353 DOI: 10.1016/j.bmc.2012.07.019  1
2012 Beaulieu PL, Bös M, Cordingley MG, Chabot C, Fazal G, Garneau M, Gillard JR, Jolicoeur E, LaPlante S, McKercher G, Poirier M, Poupart MA, Tsantrizos YS, Duan J, Kukolj G. Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV). Journal of Medicinal Chemistry. 55: 7650-66. PMID 22849725 DOI: 10.1021/jm3006788  1
2012 Lin YS, Park J, De Schutter JW, Huang XF, Berghuis AM, Sebag M, Tsantrizos YS. Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells. Journal of Medicinal Chemistry. 55: 3201-15. PMID 22390415 DOI: 10.1021/jm201657x  1
2011 Beaulieu PL, Chabot C, Duan J, Garneau M, Gillard J, Jolicoeur E, Poirier M, Poupart MA, Stammers TA, Kukolj G, Tsantrizos YS. Indole 5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase with nanomolar potency in cell-based subgenomic replicons (part 2): central amino acid linker and right-hand-side SAR studies. Bioorganic & Medicinal Chemistry Letters. 21: 3664-70. PMID 21592789 DOI: 10.1016/j.bmcl.2011.04.082  1
2010 LaPlante SR, Gillard JR, Jakalian A, Aubry N, Coulombe R, Brochu C, Tsantrizos YS, Poirier M, Kukolj G, Beaulieu PL. Importance of ligand bioactive conformation in the discovery of potent indole-diamide inhibitors of the hepatitis C virus NS5B. Journal of the American Chemical Society. 132: 15204-12. PMID 20942454 DOI: 10.1021/ja101358s  1
2010 De Schutter JW, Zaretsky S, Welbourn S, Pause A, Tsantrizos YS. Novel bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase. Bioorganic & Medicinal Chemistry Letters. 20: 5781-6. PMID 20801032 DOI: 10.1016/j.bmcl.2010.07.133  1
2009 Tsantrizos YS. TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection. Current Opinion in Investigational Drugs (London, England : 2000). 10: 871-81. PMID 19649931  1
2008 Tsantrizos YS. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus. Accounts of Chemical Research. 41: 1252-63. PMID 18681464 DOI: 10.1021/ar8000519  1
2006 Tsantrizos YS, Ferland JM, McClory A, Poirier M, Farina V, Yee NK, Wang Xj, Haddad N, Wei X, Xu J, Zhang L. Olefin ring-closing metathesis as a powerful tool in drug discovery and development - potent macrocyclic inhibitors of the hepatitis C virus NS3 protease Journal of Organometallic Chemistry. 691: 5163-5171. DOI: 10.1016/j.jorganchem.2006.09.027  1
2005 Poirier M, Aubry N, Boucher C, Ferland JM, LaPlante S, Tsantrizos YS. RCM of tripeptide dienes containing a chiral vinylcyclopropane moiety: impact of different Ru-based catalysts on the stereochemical integrity of the macrocyclic products. The Journal of Organic Chemistry. 70: 10765-73. PMID 16355998 DOI: 10.1021/jo051706k  1
2005 Fader LD, Tsantrizos YS. Modifications of peptide nucleic acid (PNA) monomers as a strategy for modulating the physicochemical and pharmacokinetic properties of PNA oligomers Chimica Oggi. 23: 40-44.  1
2004 Beaulieu PL, Tsantrizos YS. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections. Current Opinion in Investigational Drugs (London, England : 2000). 5: 838-50. PMID 15600240  1
2004 Tsantrizos YS. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic. Biopolymers. 76: 309-23. PMID 15386268 DOI: 10.1002/bip.20127  1
2004 LaPlante SR, Jakalian A, Aubry N, Bousquet Y, Ferland JM, Gillard J, Lefebvre S, Poirier M, Tsantrizos YS, Kukolj G, Beaulieu PL. Binding mode determination of benzimidazole inhibitors of the hepatitis C virus RNA polymerase by a structure and dynamics strategy. Angewandte Chemie (International Ed. in English). 43: 4306-11. PMID 15368379 DOI: 10.1002/anie.200460326  1
2004 Goudreau N, Brochu C, Cameron DR, Duceppe JS, Faucher AM, Ferland JM, Grand-Maître C, Poirier M, Simoneau B, Tsantrizos YS. Potent inhibitors of the hepatitis C virus NS3 protease: design and synthesis of macrocyclic substrate-based beta-strand mimics. The Journal of Organic Chemistry. 69: 6185-201. PMID 15357576 DOI: 10.1021/jo049288r  1
2004 Faucher AM, Bailey MD, Beaulieu PL, Brochu C, Duceppe JS, Ferland JM, Ghiro E, Gorys V, Halmos T, Kawai SH, Poirier M, Simoneau B, Tsantrizos YS, Llinàs-Brunet M. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans. Organic Letters. 6: 2901-4. PMID 15330643 DOI: 10.1021/ol0489907  1
2004 Llinàs-Brunet M, Bailey MD, Bolger G, Brochu C, Faucher AM, Ferland JM, Garneau M, Ghiro E, Gorys V, Grand-Maître C, Halmos T, Lapeyre-Paquette N, Liard F, Poirier M, Rhéaume M, ... Tsantrizos YS, et al. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. Journal of Medicinal Chemistry. 47: 1605-8. PMID 15027850 DOI: 10.1021/jm0342414  1
2004 Fader LD, Myers EL, Tsantrizos YS. Synthesis of novel analogs of aromatic peptide nucleic acids (APNAs) with modified conformational and electrostatic properties Tetrahedron. 60: 2235-2246. DOI: 10.1016/j.tet.2004.01.026  1
2003 Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bös M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagacé L, ... ... Tsantrizos YS, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 426: 186-9. PMID 14578911 DOI: 10.1038/nature02099  1
2003 Tsantrizos YS, Bolger G, Bonneau P, Cameron DR, Goudreau N, Kukolj G, LaPlante SR, Llinàs-Brunet M, Nar H, Lamarre D. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angewandte Chemie (International Ed. in English). 42: 1356-60. PMID 12671967 DOI: 10.1002/anie.200390347  1
2002 Fader LD, Tsantrizos YS. Hybridization properties of aromatic peptide nucleic acids: a novel class of oligonucleotide analogues. Organic Letters. 4: 63-6. PMID 11772091 DOI: 10.1021/ol010231q  1
2001 Poupart MA, Cameron DR, Chabot C, Ghiro E, Goudreau N, Goulet S, Poirier M, Tsantrizos YS. Solid-phase synthesis of peptidomimetic inhibitors for the hepatitis C virus NS3 protease. The Journal of Organic Chemistry. 66: 4743-51. PMID 11442398 DOI: 10.1021/jo010164d  1
2001 Fader LD, Boyd M, Tsantrizos YS. Backbone modifications of aromatic peptide nucleic acid (APNA ) monomers and their hybridization properties with DNA and RNA. The Journal of Organic Chemistry. 66: 3372-9. PMID 11348119 DOI: 10.1021/jo001650o  1
2000 Tsantrizos YS, Yang XS. Chapter Four Macrolide and polyether polyketides biosynthesis and molecular diversity Recent Advances in Phytochemistry. 34: 91-107. DOI: 10.1016/S0079-9920(00)80005-2  1
1999 Tsantrizos YS, Yang X, McClory A. Studies on the Biosynthesis of the Fungal Metabolite Oudenone. 2. Synthesis and Enzymatic Cyclization of an alpha-Diketone, Open-Chain Precursor into Oudenone in Cultures of Oudemansiella radicata. The Journal of Organic Chemistry. 64: 6609-6614. PMID 11674663  0.84
1999 Tsantrizos YS, Yang X, McClory A. Studies on the biosynthesis of the fungal metabolite oudenone. 2. Synthesis and enzymatic cyclization of an α-diketone, open-chain precursor into oudenone in cultures of Oudemansiella radicata Journal of Organic Chemistry. 64: 6609-6614. DOI: 10.1021/jo9901135  1
1997 Tsantrizos YS, Shen J, Trimble LA. Biosynthetic origin of the tetrahydropyranyl side chain of verucopeptin Tetrahedron Letters. 38: 7033-7036. DOI: 10.1016/S0040-4039(97)01661-4  1
1997 Tsantrizos YS, Chew W, Colebrook LD, Sauriol F. Synthesis of a novel 1,4-bridged calix[8]arene 'host' cavity Tetrahedron Letters. 38: 5411-5414. DOI: 10.1016/S0040-4039(97)01202-1  1
1997 Tsantrizos YS, Lunetta JF, Boyd M, Fader LD, Wilson MC. Stereoselective Synthesis of a Thymine Derivative of (S)-2-Hydroxy-4-(2-aminophenyl)butanoic Acid. A Novel Building Block for the Synthesis of Aromatic Peptidic Nucleic Acid Oligomers Journal of Organic Chemistry. 62: 5451-5457.  1
1997 Alexakis T, Tsantrizos PG, Tsantrizos YS, Meunier JL. Synthesis of fullerenes via the thermal plasma dissociation of hydrocarbons Applied Physics Letters. 70: 2102-2104.  1
1996 Tsantrizos YS, Pischos S, Sauriol F. Structural assignment of the peptide antibiotic LP237-F8, a metabolite of Tolypocladium geodes Journal of Organic Chemistry. 61: 2118-2121. DOI: 10.1021/jo951837t  1
1996 Cane DE, Tsantrizos YS. Aristolochene synthase. Elucidation of the cryptic germacrene A synthase activity using the anomalous substrate dihydrofarnesyl diphosphate Journal of the American Chemical Society. 118: 10037-10040. DOI: 10.1021/ja961981b  1
1996 Cane DE, Xue Q, Van Epp JE, Tsantrizos YS. Enzymatic formation of isochamigrene, a novel sesquiterpene, by alteration of the aspartate-rich region of trichodiene synthase Journal of the American Chemical Society. 118: 8499-8500. DOI: 10.1021/ja961897w  1
1996 Tsantrizos YS. Peptaibol metabolites of Tolypocladium geodes Canadian Journal of Chemistry. 74: 165-172.  1
1995 Tsantrizos YS. Bioactive metabolites of the genus Phomopsis Studies in Natural Products Chemistry. 15: 341-359. DOI: 10.1016/S1572-5995(06)80136-5  1
1995 Tsantrizos YS, Zhou F, Famili P, Yang X. Biosynthesis of the hypotensive metabolite oudenone by Oudemansiella radicata. 1. Intact incorporation of a tetraketide chain elongation intermediate Journal of Organic Chemistry. 60: 6922-6929.  1
1991 Kope HH, Tsantrizos YS, Fortin JA, Ogilvie KK. p-Hydroxybenzoylformic acid and (R)-(-)-p-hydroxymandelic acid, two antifungal compounds isolated from the liquid culture of the ectomycorrhizal fungus Pisolithus arhizus. Canadian Journal of Microbiology. 37: 258-64. PMID 1913337  1
1991 Tsantrizos YS, Kope HH, Fortin JA, Ogilvie KK. Antifungal antibiotics from Pisolithus tinctorius Phytochemistry. 30: 1113-1118. DOI: 10.1016/S0031-9422(00)95183-5  1
1991 Tsantrizos YS, Ogilvie KK. Determination of the absolute stereochemistry of the fungal metabolite (R)-(-)-2-(4'-hydroxyphenyl)-2-hydroxyethanoic acid (pisolithin B) Canadian Journal of Chemistry. 69: 772-778.  1
1981 Just G, Tsantrizos YS, Ugolini A. β-Lactams. IX. The synthesis of 7-β-phenylacetamido-3'-hydroxybenzo-[3,4]-O-2-isocephem, a weak antibacterial β-lactam antibiotic Canadian Journal of Chemistry. 59: 2981-2987.  1
Show low-probability matches.